Executive Summary

The regulatory landscape for therapeutic biosimilars is changing. Under the BPCI Act of 2009, the 351(k) pathway allows biosimilar approval based on high similarity to a US-licensed reference product. In the past, this process relied on large, multi‑center clinical trials to compare safety and efficacy.

Today, advances in analytical science have shifted the U.S. FDA toward an analytical-centric model. Structural, functional, and clinical pharmacology assessments now form the core of biosimilarity assessment. Clinical endpoints are often less sensitive to small molecular differences. As a result, if a sponsor can show strong analytical similarity and bioequivalence through PK and PD data, the FDA may allow omission of Phase 3 trials in certain cases.

The Totality-of-the-Evidence Framework: An Evolving Paradigm

Regulations require a biosimilar to be highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency. Traditionally, under the foundational Scientific Considerations in Demonstrating Biosimilarity to a Reference Product guidance (April 2015), the FDA followed a stepwise model. This involved moving from analytical testing to animal studies, then to clinical pharmacology and large clinical trials.

Today, this pyramid is inverted and more flexible. The FDA places greater weight on analytical characterization, which can detect small molecular differences (like micro-heterogeneity in glycosylation) more precisely than clinical trials. Instead of a fixed sequence, the process is now risk-based. If analytical and PK/PD data reduce uncertainty enough, the need for large clinical trials becomes less important.

Analytical Structural and Functional Characterization

To reduce or bypass clinical trials, sponsors must build a strong analytical foundation. They should use orthogonal methods to compare the proposed biosimilar with the reference product. Under the FDA’s Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment framework (Sep 2025), this requires a rigorous, multi-dimensional assessment. The assessment should use separate testing methods that evaluate the same product features through different physical or chemical attributes.

Primary and Higher-Order Structures

Sponsors must demonstrate identical primary amino acid sequences. Deviations (except for minor C-terminal truncations that do not alter biological function) can disqualify a molecule from the 351(k) pathway. Higher-order structures (HOS) must also be carefully mapped:

• Secondary and Tertiary Structure: Evaluated via Far- & Near-UV Circular Dichroism, Fourier Transform Infrared (FTIR) spectroscopy, and Nuclear Magnetic Resonance (NMR) spectroscopy to confirm identical protein folding.
• Quaternary Structure and Aggregation: Measured using Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS) and Analytical Ultracentrifugation (AUC) to detect immunogenic aggregates and fragments.

Glycosylation Profiles

For glycoproteins, particularly monoclonal antibodies, carbohydrate moieties attached to the Fc region affect stability and function. Sponsors must use Hydrophilic Interaction Liquid Chromatography (HILIC) and High-Performance Anion-Exchange Chromatography (HPAEC-PAD) to map:

• Afucosylation: Increases Fc receptor binding and Antibody-Dependent Cellular Cytotoxicity (ADCC).
• Galactosylation and Sialylation: Variations influence serum half-life and anti-inflammatory activity.
• High-Mannose Structures: Elevated levels accelerate drug clearance, directly altering PK profiles.

Functional Bioassays and Binding Kinetics

Analytical similarity must include functional equivalence. Structural similarity alone is not sufficient. Sponsors should use a range of functional assays that reflect all known mechanisms of action of the reference product:

• Receptor Binding Affinity: Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI) can be used to measure how strongly and how quickly the biosimilar binds to its targets. This includes binding kinetics parameters (K_D, k_on, k_off) for target antigens and Fc receptors (FcγRI, FcγRII, FcγRIIIa/b, FcRn).
• Cell-Based Potency Assays: They measure effects such as target neutralization, inhibition of cell growth, or induction of cell death. Automated assays like ADCC and Complement‑Dependent Cytotoxicity (CDC) are used to confirm that the biosimilar matches the reference product in activity.

Clinical Pharmacology (PK/PD) as Sensitive Endpoints

Once analytical similarity is established, development moves to clinical pharmacology studies. Per Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product guidance (Dec 2016), these studies demonstrate bioequivalence and resolve any remaining uncertainty.

Pharmacokinetic (PK) Evaluation

Sponsors utilize randomized, single-dose, cross-over studies in healthy volunteers (or parallel group designs for drugs with long half-lives or high immunogenicity risks). Primary PK endpoints include:

• Area Under the Curve (AUC_0-∞ or AUC_0-t): Reflects total systemic exposure.
• Maximum Observed Plasma Concentration (C_max): Reflects peak exposure.

Bioequivalence is established when the 90% confidence interval falls within the 80–125% acceptance criteria range.

Pharmacodynamic (PD) Evaluation

PD biomarkers provide an additional layer of evidence. When validated biomarkers are available, they can act as surrogates for clinical efficacy (e.g., absolute neutrophil count for filgrastim). In such cases, PD data can support the decision to exclude Phase 3 trials.

When is a Comparative Clinical Trial Not Required?

This reflects a shift toward evidence-driven development rather than routine reliance on clinical trials.

Immunogenicity Assessment in the Modern Regulatory Era

Even when clinical trials are waived, immunogenicity must be evaluated. Sponsors should follow a risk-based approach using PK/PD study samples. This includes:

1. Screening Assay: Typically an ECL or ELISA with high sensitivity and a pre-set 5% false-positive rate.
2. Confirmatory Assay: Uses competitive displacement with the study drug to eliminate non-specific binding.
3. Titer & Neutralizing Antibody (NAb) Assay: Tests response strength and uses functional cell-based or ligand-binding assays to determine if anti-drug antibodies (ADAs) block the drug’s MoA.

The regulatory goal is to show that immunogenicity is no greater than that of the reference product. Matching ADA incidence, titers, and clinical consequences during the PK/PD phase satisfies these requirements.

Strategic Implications for Biosimilar Sponsors

The shift toward analytical-heavy approval pathways is changing the development strategy. Sponsors must invest more in CMC and analytical capabilities, than in large clinical trials.

Key Strategic Pillars:

• Prioritize Reference Product Sourcing: Analyze multiple reference product lots over a 2-to-3-year window to capture manufacturing lifecycle variations and establish achievable statistical margins.
• Invest Early in Orthogonal Technologies: Use a diverse analytical matrix early (e.g., verifying aggregation via both SEC-HPLC and AUC) to eliminate unexpected structural discrepancies before final regulatory review.
• Engage the FDA Early: Use formal Biosimilar User Fee Act (BsUFA) meeting pathways. Presenting a comprehensive analytical bridging data package during a Type 2 meeting allows sponsors to secure formal FDA concurrence on clinical trial waivers before starting human PK testing.

How BLA Regulatory Can Help

BLA Regulatory LLC provides technical and strategic consulting to de-risk cell and gene therapy programs by bridging early manufacturing changes to BLA readiness. Our senior consultants can help secure early FDA alignment on CQAs, analytical methods, and material transitions through formal FDA meetings. We deliver comprehensive CMC medical writing to author robust comparability protocols for CTD Module 3, paired with end-to-end lifecycle management spanning IND maintenance, eCTD compiling, and pre-approval inspection readiness. Partner with BLA Regulatory to optimize your modern, analytical-centric regulatory pathway and accelerate market approval.

This newsletter is for informational purposes only and does not constitute formal legal or regulatory advice.